XENETIC BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
XENETIC BIOSCIENCES, INC. (XBIO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $122.68 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-03-18
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $122.68K, a 54.82% decline from fiscal 2023.
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $271.55K, a 37.74% increase from fiscal 2022.
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $197.15K, a 77.90% increase from fiscal 2021.
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2021 was $110.82K, a 7821.44% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2024-12-31 | $122.68K 10-K · filed 2025-03-18 |
| 2023-12-31 | $271.55K 10-K · filed 2025-03-18 |
| 2022-12-31 | $197.15K 10-K · filed 2024-03-21 |
| 2021-12-31 | $110.82K 10-K · filed 2023-03-22 |
| 2020-12-31 | $1.40K 10-K · filed 2022-03-22 |
| 2019-12-31 | $1.32K 10-K · filed 2021-03-16 |
| 2018-12-31 | $40.02K 10-K · filed 2020-03-26 |
| 2017-12-31 | $162.54K 10-K · filed 2019-03-29 |
| 2016-12-31 | $780.84K 10-K · filed 2018-03-30 |
| 2015-12-31 | $800.89K 10-K · filed 2017-03-31 |
| 2014-12-31 | -$1.53M 10-K · filed 2016-03-30 |
| 2013-12-31 | $674.92K 10-K · filed 2015-07-20 |
| 2012-12-31 | $99.83K 10-K · filed 2015-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |